Combined approaches to treating external genital warts in women
- Авторлар: Gasanova G.F.1, Apolikhina I.A.1,2, Dodova E.G.1, Gorbunova E.A.1
-
Мекемелер:
- Academician V.I. Kulakov Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia
- I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
- Шығарылым: № 3 (2017)
- Беттер: 65-71
- Бөлім: Articles
- URL: https://journals.eco-vector.com/2226-6976/article/view/278622
- ID: 278622
Дәйексөз келтіру
Ашық рұқсат
Рұқсат берілді
Аннотация
Objective. To optimize approaches to preventing recurrent pointed condylomas (PC) of the external female genitalia after destructive therapy. Subjects and methods. A bicenter randomized open-label controlled comparative study was conducted. It included 93 patients with PC of the external genitalia, who were divided into 3 groups after CO2 laser destruction of PC. Group 1 (n = 31) received combined therapy with interferon-а (IEN-а) as rectal suppositories for 10 days in combination with oral indole-3-carbinol (I3C) tablets for 6 months. For the prevention of recurrent PC, Group 2 (n = 31) had only standard immunomodulatory therapy with IEN-а as rectal suppositories. A control group (n = 31) did not use pharmacotherapy. The investigators carried out photo fixation of PC and qualitative tests for human papillomavirus (HPV) by a PCR assay. Results. Six months after destruction, the PC recurrence rates were 6.5% in Group 1, 25.8% in Group 2, and 32.3% in the control group (p = 0.010). None of the groups were found to have recurrent PC at 12 months following treatment initiation. According to the data of HPV diagnosis (a common qualitative test), after the therapy within a 12-month follow-up, the viral elimination rates were 85.7% in Group 1, 66.66% in Group 2, and 54.54% in the control group. After 12 months of treatment initiation, the HPV types 6 and 11 elimination rates were 87.5% in Group 1, 85.7% in Group 2, and 75.0% in the control group. In these groups, HPV types 31 and 33 were eliminated in 83.3, 80, and 100% of cases, respectively. The high-risk HPV types 16 and 18 elimination rates were 100, 83.3, and 0%, respectively. Conclusion. There was a statistically significant reduction in the rate of recurrent PC of the external female genitalia, as well as HPV elimination and reduced reinfection especially with high-risk HPV types 16 and 18 during combined therapy with I3C and IFN-a. A combination of I3C and IFN-a showed a higher efficacy than the conventional use of IFN-a only.
Негізгі сөздер
Толық мәтін
Авторлар туралы
Gulnar Gasanova
Academician V.I. Kulakov Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia
Email: g_gasanova@oparina4.ru
Postgraduate Student
Inna Apolikhina
Academician V.I. Kulakov Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Email: i_apolikhina@oparina4.ru
MD, Head, Department of Aesthetic Gynecology and Rehabilitation; Prof., Department of Obstetrics, Gynecology, and Reproductology
Elena Dodova
Academician V.I. Kulakov Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia
Email: adeli575@mail.ru
Postgraduate Student
Elena Gorbunova
Academician V.I. Kulakov Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia
Email: el_gorbunova@oparina4.ru
Obstetrician-Gynecologist
Әдебиет тізімі
- Прилепская В.Н., ред. Заболевания шейки матки (клинические лекции). М: Медиа Сфера, 1997. 882 с.
- Лопухов П.Д., Брико Н.И., Цапкова Н.Н., Халдин А.А., Жукова О.В., Исаева Д.Р., Лупашко О.В. Злокачественные и доброкачественные новообразования, обусловленные вирусом папилломы человека, в Российской Федерации и в Москве. Эпидемиол. инфекц. болезни. Актуал. вопр. 2016; (4): 52-6. (In Russ.).
- Кубанова А.А., Кубанов А.А., Мелехина Л.Е., Богданова Е.В. Дерматовенерология в Российской Федерации. Итоги 2014 года. Успехи, достижения. Основные пути развития. Вестник дерматологии и венерологии 2015; (4): 13-26.
- Patel H., Wagner M., Singhal P., Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis. 2013; 13: 39.
- Park I.U., Introcaso C., Dunne E.F. Human Papillomavirus and Genital Warts: а Review of the Evidence for the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines. Clin. Infect. Dis. 2015; 61(suppl. 8): 849-55.
- Bosch F.X., Broker T.R., Forman D., Moscicki A.-B., Gillison M.L., Doorbar J., Stern P.L. Comprehensive Control of Human Papillomavirus infections and Related Diseases. Vaccine 2013; 31(suppl.7): 3-31.
- Кулаков В.И., ред. Национальное руководство по гинекологии. М.: ГЭОТАР-Медиа; 2007: 482-3.
- Systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis. 2009; 9: 119.
- Руководство по лечению заболеваний, передаваемых половым путем: Пер. с англ. Ассоциация по борьбе с заболеваниями, передаваемыми половым путем -САНАМ. М.: Венера-пресс, 1998. 136 с.
- Российское общество дерматовенерологов и косметологов. Федеральные клинические рекомендации. Дерматовенерология. Болезни кожи и инфекции, передаваемые половым путем. М.: Издательский дом «ДЕЛОВОЙ ЭКСПРЕСС», 2016; 635-45.
- Аполихина И.А. Оптимизация лечебных и диагностических мероприятий при папилломавирусной инфекции. Автореф. дис.. канд. мед. наук. М., 1999.
- Auborn K.J., Woodworth C., DiPaolo J.A., Bradlow H.L. The interaction between HPV infection and estrogen metabolism in cervical carcinogenesis. Int. J. Cancer 1991; 49(6): 867.
- Lawrence J.A., Malpas P.B., Sigman C.C., Kelloff G.J. Clinical development of estrogen modulators for breast cancer chemoprevention in premenopausal vs. postmenopausal women. Cell Biochem. 2000; 34(Suppl.1): 103-14.
- Stern P.L., van der Burg S.H., Hampson I.N., Broker T.R., Fiander A., Lacey C.J., Kitchener H.C., Einstein M.H. Therapy of human papillomavirus-related disease. Vaccine 2012; 30(Suppl.5): 71-82.
- Исаков В.А., Ермоленко Д.К., Ермоленко Е.И. Герпесвирусные и папилломавирусные инфекции. В кн.: Аковбян В.А., Прохоренков В.И., Соколовский Е.В., ред. Инфекции, передаваемые половым путем. М.: Медиа Сфера; 2007: 448-513.
- Прилепская В.Н., Довлетханова Э.Р. Особенности диагностики, клинической картины и лечения заболеваний, ассоциированных с папилломавирусной инфекцией. Гинекология 2013; 15(5): 7-12.
- Киселев В.И., Дмитриев Г.А., Кубанова А.А. Взаимосвязь вирусных инфекций, передаваемых половым путем, и онкологических заболеваний урогенитального тракта. Вестник дерматологии и венерологии 2000; (6): 20-3.
- Шперлинг Н.В., Венгеровский А.И., Персидская О.А., Шперлинг И.А. Опыт применения индинола при рецидивирующей папилломавирусной инфекции гениталий. Клиническая дерматология и венерология 2009; (2): 32-6.
- Стрижаков А.Н., Давыдов А.И. Гинекология. Курс лекций. М.: ГЭОТАР-Медиа; 2009: 91-7.
- Долгушина В.В., Ахматова А.Н., Беренда М.А. Эффективность изопринозина в лечении хронического цервицита, ассоциированного с папилломавирусной инфекцией. Фарматека 2009; (14): 73-6.
Қосымша файлдар
